These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21070597)

  • 1. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
    McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
    J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
    McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
    Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.
    Liu Q; Chen H; Ojode T; Gao X; Anaya-O'Brien S; Turner NA; Ulrick J; DeCastro R; Kelly C; Cardones AR; Gold SH; Hwang EI; Wechsler DS; Malech HL; Murphy PM; McDermott DH
    Blood; 2012 Jul; 120(1):181-9. PubMed ID: 22596258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4.
    Luo J; De Pascali F; Richmond GW; Khojah AM; Benovic JL
    J Biol Chem; 2022 Feb; 298(2):101551. PubMed ID: 34973340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHIM Syndrome Caused by Waldenström's Macroglobulinemia-Associated Mutation CXCR4 (L329fs).
    Liu Q; Pan C; Lopez L; Gao J; Velez D; Anaya-O'Brien S; Ulrick J; Littel P; Corns JS; Ellenburg DT; Malech HL; Murphy PM; McDermott DH
    J Clin Immunol; 2016 May; 36(4):397-405. PubMed ID: 27059040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.
    de Wit RH; Heukers R; Brink HJ; Arsova A; Maussang D; Cutolo P; Strubbe B; Vischer HF; Bachelerie F; Smit MJ
    J Pharmacol Exp Ther; 2017 Oct; 363(1):35-44. PubMed ID: 28768817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filamin A interaction with the CXCR4 third intracellular loop regulates endocytosis and signaling of WT and WHIM-like receptors.
    Gómez-Moutón C; Fischer T; Peregil RM; Jiménez-Baranda S; Stossel TP; Nakamura F; Mañes S
    Blood; 2015 Feb; 125(7):1116-25. PubMed ID: 25355818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome.
    Kawai T; Choi U; Whiting-Theobald NL; Linton GF; Brenner S; Sechler JM; Murphy PM; Malech HL
    Exp Hematol; 2005 Apr; 33(4):460-8. PubMed ID: 15781337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics on a WHIM.
    Al Ustwani O; Kurzrock R; Wetzler M
    Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
    Dotta L; Tassone L; Badolato R
    Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.
    Galli J; Pinelli L; Micheletti S; Palumbo G; Notarangelo LD; Lougaris V; Dotta L; Fazzi E; Badolato R
    Orphanet J Rare Dis; 2019 Feb; 14(1):61. PubMed ID: 30819232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
    McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
    Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation.
    Zmajkovicova K; Nykamp K; Blair G; Yilmaz M; Walter JE
    Front Immunol; 2024; 15():1411141. PubMed ID: 39040098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse.
    Kallikourdis M; Trovato AE; Anselmi F; Sarukhan A; Roselli G; Tassone L; Badolato R; Viola A
    Blood; 2013 Aug; 122(5):666-73. PubMed ID: 23794067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.
    Kawai T; Choi U; Cardwell L; DeRavin SS; Naumann N; Whiting-Theobald NL; Linton GF; Moon J; Murphy PM; Malech HL
    Blood; 2007 Jan; 109(1):78-84. PubMed ID: 16946301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromothriptic cure of WHIM syndrome.
    McDermott DH; Gao JL; Liu Q; Siwicki M; Martens C; Jacobs P; Velez D; Yim E; Bryke CR; Hsu N; Dai Z; Marquesen MM; Stregevsky E; Kwatemaa N; Theobald N; Long Priel DA; Pittaluga S; Raffeld MA; Calvo KR; Maric I; Desmond R; Holmes KL; Kuhns DB; Balabanian K; Bachelerie F; Porcella SF; Malech HL; Murphy PM
    Cell; 2015 Feb; 160(4):686-699. PubMed ID: 25662009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.
    Liu Q; Li Z; Y Yang A; Gao JL; S Velez D; J Cho E; McDermott DH; Murphy PM
    J Clin Immunol; 2018 Jan; 38(1):77-87. PubMed ID: 29177911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4
    Zmajkovicova K; Pawar S; Maier-Munsa S; Maierhofer B; Wiest I; Skerlj R; Taveras AG; Badarau A
    Genes Immun; 2022 Sep; 23(6):196-204. PubMed ID: 36089616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs.
    Majumdar S; Pontejo SM; Jaiswal H; Gao JL; Salancy A; Stassenko E; Yamane H; McDermott DH; Balabanian K; Bachelerie F; Murphy PM
    J Immunol; 2023 Jun; 210(12):1913-1924. PubMed ID: 37133343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
    McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
    J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.